Novartis AG (NVS)
NYSE: NVSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
NVS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $272.33B
- P/E (TTM)
- 21.64
- Forward P/E
- 14.63
- EPS (TTM)
- $6.62
- Dividend yield
- 3.26% ($4.67)
- Ex-dividend date
- Mar 11, 2026
- 52-week range
- 121.57 – 170.46
- Day range
- 142.55 – 144.28
- Volume / Avg
- 1.85M / 1.96M
- Beta
- —
- Shares outstanding
- 1.90B
- Next earnings
- Oct 27, 2026
52-week range
NVS stock today
Shares of Novartis (NVS) finished higher on Oct 7 at $143.28, a gain of 1.77% or $2.49 per share, versus the S&P 500's 0.22% decline. Shares are 15.9% below their 52-week high of $170.46, set on Feb 27, 2026 and 17.9% above the 52-week low of $121.57, in the middle of the past year's range. NVS is up 3.9% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 8.9%.
At 21.6x trailing earnings, Novartis trades below the peer-group median of 26.7x. Its forward P/E of 14.6x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 27 before the market opens; analysts expect EPS of $2.25. Novartis pays an annual dividend of $4.67 per share, a 3.26% yield at the current price.
Summary generated from market data by MetaCap's automated system. Methodology
About Novartis
Company profileNovartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Vasant Narasimhan M.D.
- Headquarters
- Basel
- Employees
- 75,267
- Website
- novartis.com
Financial highlights
Full financialsNet income was $13.98 billion (+17.1% year over year). Diluted earnings per share came in at $7.15, up from $5.87.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $13.98B | $11.94B | $14.85B | $6.96B | $24.02B |
| EPS (diluted) | $7.15 | $5.87 | $7.10 | $3.17 | $10.63 |
Analyst forecast
ForecastConsensus (12 analysts)
hold
Avg. price target
$155.01+8.19%
- Strong buy 3
- Buy 2
- Hold 6
- Sell 1
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 27, 2026
- EPS estimate
- $2.25
Dividends
Dividend history- Annual dividend
- $4.67
- Dividend yield
- 3.26%
- Last payment
- $4.77
- Ex-dividend date
- Mar 11, 2026
NVS news
All NVS news- Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen DealNasdaqNVS, IONS, ACIU, PGEN
- Novartis Signs Deal With Abogen For MRNA TherapiesNasdaq
- Agios' Growth Story Hinges on Mitapivat's Commercial ExpansionNasdaqAGIO, NVS, BMY, NVO
- Novartis inks up to $7.8B deal with Abogen for RNA-encoded therapeuticsSeeking Alpha
- Will Vertex's Kidney Disease Pipeline Be a New Growth Engine?NasdaqVRTX, NVS, VERA
- Ionis Delivers Positive Late-Stage Results for Two Partnered DrugsNasdaqIONS, AZN, NVS
- BoomRay Pharma, Novartis Ink Radioligand Therapy Licensing Deal Worth Up To $900 MlnNasdaq
- NVS Gets Positive CHMP Opinion for Cosentyx for Another IndicationNasdaqNVS, RGEN, ANIK, IONS
Novartis peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AZNAstraZeneca PLC | 160.12 | +0.95% | $248.33B | vs NVS |
| MRKMerck & Company Inc. | 142.79 | +0.60% | $352.29B | vs NVS |
| ABTAbbott Laboratories | 98.73 | +0.58% | $170.84B | vs NVS |
| NVONovo Nordisk A/S | 38.26 | +1.95% | $168.89B | vs NVS |
| PFEPfizer Inc. | 28.00 | +1.82% | $159.59B | vs NVS |
| VRTXVertex Pharmaceuticals Incorporated | 505.64 | +0.66% | $128.16B | vs NVS |
| BMYBristol-Myers Squibb Company | 59.70 | +0.18% | $121.95B | vs NVS |
| SNYSanofi ADS | 40.20 | +1.62% | $96.32B | vs NVS |
Indexes, lists and sector
Novartis stock FAQ
What is Novartis's stock price today?
NVS last traded at $143.28 as of Oct 7, 4:00 PM EDT, up 1.77% on the day. Prices are delayed at least 15 minutes.
Does Novartis pay a dividend?
Yes. Novartis pays $4.67 per share annually, a 3.26% yield. The most recent dividend of $4.77 had an ex-dividend date of Mar 11, 2026.
When is Novartis's next earnings date?
Novartis is expected to report earnings on Tuesday, October 27, 2026. Analysts expect EPS of $2.25.
What is NVS's P/E ratio?
NVS trades at a trailing P/E ratio of 21.64 and a forward P/E of 14.63, compared with a median of 26.7 for its closest peers.
Who is Novartis's CEO?
Dr. Vasant Narasimhan M.D. is the chief executive officer of Novartis AG, which has about 75,267 employees.
Has NVS ever split its stock?
Yes. The most recent NVS stock split was a 1116-for-1000 split on Apr 9, 2019, one of 2 splits on record.
What is the NVS 52-week high?
The 52-week high for NVS is $170.46 and the 52-week low is $121.57. The stock is currently 15.9% below its high.